This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

EMC, Jazz Pharma: Analysts' New Ratings

Stocks in this article: EMC EWBC EXC JAZZ VRTX VOD VHS

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Amyris (AMRS) upgraded at Morgan Stanley from Equal-weight to Overweight. $32 price target. Company continues to execute on its growth strategy.

Cameron International (CAM) upgraded at Credit Suisse from Neutral to Outperform. $73 price target. Very strong orders.

EMC (EMC) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Stock is attractive, following a recent pullback.

East West Bancorp (EWBC) upgraded at FBR from Market Perform to Outperform. $23 price target. Stock is attractively valued, following a recent pullback.

Exelon (EXC) upgraded at UBS from Neutral to Buy. $50 price target. Cost synergy story and leverage to power recovery.

Jazz Pharmaceuticals (JAZZ) upgraded at Jefferies to Buy. $52 price target. Estimates also upped, given recent Xyrem growth.

Oceaneering International (OII) downgraded at Credit Suisse from Outperform to Neutral. $48 price target. Central theses played out.

Oil States (OIS) upgraded at Credit Suisse from Neutral to Outperform. $110 price target. Stock should continue to deliver higher earnings.

Rockwell Automation (ROK) upgraded at Baird from Neutral to Outperform. $92 price target. Company can continue to deliver solid growth over the coming years.

RadioShack (RSH) upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction Buy list. $18 price target. Company is improving its position in the wireless market.

Vanguard Health (VHS) rated new Overweight at JP Morgan. $22 price target. Company has attractive exposure to urban markets.

Vodafone (VOD) upgraded at UBS from Neutral to Buy. $31.05 price target. VZW dividend larger than expected.

Vertex Pharmaceuticals (VRTX) upgraded at Citigroup from Hold to Buy. $60 price target. Incivek should not disappoint.



End of report.

This article was written by a staff member of TheStreet.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs